385 related articles for article (PubMed ID: 37520534)
21. Prediction of Prognosis and Immunotherapy Response with a Novel Natural Killer Cell Marker Genes Signature in Osteosarcoma.
Li Q; Huang X; Zhao Y
Cancer Biother Radiopharm; 2023 Oct; ():. PubMed ID: 37889617
[No Abstract] [Full Text] [Related]
22. CDKN2A-mediated molecular subtypes characterize the hallmarks of tumor microenvironment and guide precision medicine in triple-negative breast cancer.
Cheng T; Wu Y; Liu Z; Yu Y; Sun S; Guo M; Sun B; Huang C
Front Immunol; 2022; 13():970950. PubMed ID: 36052076
[TBL] [Abstract][Full Text] [Related]
23. Integrated analysis of single-cell and bulk RNA-sequencing reveals a novel signature based on NK cell marker genes to predict prognosis and immunotherapy response in gastric cancer.
Sun JR; Kong CF; Ye YX; Wang Q; Qu XK; Jia LQ; Wu S
Sci Rep; 2024 Apr; 14(1):7648. PubMed ID: 38561388
[TBL] [Abstract][Full Text] [Related]
24. Development of an ubiquitin-proteasome system signature for predicting prognosis and providing therapeutic guidance for patients with triple-negative breast cancer.
Chen X; Ren C; Zhou Z; Chen J; Fan X; Li X; Chen J; Zhu J
J Gene Med; 2024 Jan; 26(1):e3584. PubMed ID: 37605934
[TBL] [Abstract][Full Text] [Related]
25. Identification of necroptosis-related subtypes and prognosis model in triple negative breast cancer.
Pu S; Zhou Y; Xie P; Gao X; Liu Y; Ren Y; He J; Hao N
Front Immunol; 2022; 13():964118. PubMed ID: 36059470
[TBL] [Abstract][Full Text] [Related]
26. Role of ICAM1 in tumor immunity and prognosis of triple-negative breast cancer.
Zhou Q; Xu J; Xu Y; Sun S; Chen J
Front Immunol; 2023; 14():1176647. PubMed ID: 37671167
[TBL] [Abstract][Full Text] [Related]
27. Triple-Negative Breast Cancer Analysis Based on Metabolic Gene Classification and Immunotherapy.
Zhou Y; Che Y; Fu Z; Zhang H; Wu H
Front Public Health; 2022; 10():902378. PubMed ID: 35875026
[TBL] [Abstract][Full Text] [Related]
28. A novel immune checkpoint-related gene signature for predicting overall survival and immune status in triple-negative breast cancer.
Liu J; Ling Y; Su N; Li Y; Tian S; Hou B; Luo S; Zhao L; Shi M
Transl Cancer Res; 2022 Jan; 11(1):181-192. PubMed ID: 35261895
[TBL] [Abstract][Full Text] [Related]
29. A novel natural killer-related signature to effectively predict prognosis in hepatocellular carcinoma.
Xi D; Wang J; Yang Y; Ji F; Li C; Yan X
BMC Med Genomics; 2023 Sep; 16(1):211. PubMed ID: 37674210
[TBL] [Abstract][Full Text] [Related]
30. Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on NK cell marker genes to predict prognosis and immunotherapy response in hepatocellular carcinoma.
Yang D; Zhao F; Su Y; Zhou Y; Shen J; Yu B; Zhao K; Ding Y
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10609-10621. PubMed ID: 37296316
[TBL] [Abstract][Full Text] [Related]
31. Identification of Hypoxia-Related Subtypes, Establishment of Prognostic Models, and Characteristics of Tumor Microenvironment Infiltration in Colon Cancer.
Wang C; Tang Y; Ma H; Wei S; Hu X; Zhao L; Wang G
Front Genet; 2022; 13():919389. PubMed ID: 35783281
[No Abstract] [Full Text] [Related]
32. The prognostic marker KRT81 is involved in suppressing CD8 + T cells and predicts immunotherapy response for triple-negative breast cancer.
Yan Z; Zhong Z; Shi C; Feng M; Feng X; Liu T
Cancer Biol Ther; 2024 Dec; 25(1):2355705. PubMed ID: 38778753
[TBL] [Abstract][Full Text] [Related]
33. Tumor microenvironment characterization in triple-negative breast cancer identifies prognostic gene signature.
Qin Y; Deng J; Zhang L; Yuan J; Yang H; Li Q
Aging (Albany NY); 2021 Feb; 13(4):5485-5505. PubMed ID: 33536349
[TBL] [Abstract][Full Text] [Related]
34. Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels T cell-related prognostic risk model and tumor immune microenvironment modulation in triple-negative breast cancer.
Guo S; Liu X; Zhang J; Huang Z; Ye P; Shi J; Stalin A; Wu C; Lu S; Zhang F; Gao Y; Jin Z; Tao X; Huang J; Zhai Y; Shi R; Guo F; Zhou W; Wu J
Comput Biol Med; 2023 Jul; 161():107066. PubMed ID: 37263064
[TBL] [Abstract][Full Text] [Related]
35. Identification of DDIT4 as a potential prognostic marker associated with chemotherapeutic and immunotherapeutic response in triple-negative breast cancer.
Chen X; Li Z; Liang M; Zhang Z; Zhu D; Lin B; Zhou R; Lu Y
World J Surg Oncol; 2023 Jun; 21(1):194. PubMed ID: 37391802
[TBL] [Abstract][Full Text] [Related]
36. Model for predicting immunotherapy based on M2 macrophage infiltration in TNBC.
Wu H; Feng J; Zhong W; Zouxu X; Xiong Z; Huang W; Zhang C; Wang X; Yi J
Front Immunol; 2023; 14():1151800. PubMed ID: 36999020
[TBL] [Abstract][Full Text] [Related]
37. Identification of a Hypoxia-Related Molecular Classification and Hypoxic Tumor Microenvironment Signature for Predicting the Prognosis of Patients with Triple-Negative Breast Cancer.
Sun X; Luo H; Han C; Zhang Y; Yan C
Front Oncol; 2021; 11():700062. PubMed ID: 34490098
[TBL] [Abstract][Full Text] [Related]
38. Identification of a five genes prognosis signature for triple-negative breast cancer using multi-omics methods and bioinformatics analysis.
Ma J; Chen C; Liu S; Ji J; Wu D; Huang P; Wei D; Fan Z; Ren L
Cancer Gene Ther; 2022 Nov; 29(11):1578-1589. PubMed ID: 35474355
[TBL] [Abstract][Full Text] [Related]
39. Natural killer cell-related prognosis signature characterizes immune landscape and predicts prognosis of HNSCC.
Chi H; Xie X; Yan Y; Peng G; Strohmer DF; Lai G; Zhao S; Xia Z; Tian G
Front Immunol; 2022; 13():1018685. PubMed ID: 36263048
[TBL] [Abstract][Full Text] [Related]
40. Identification of a Gene Expression Signature to Predict the Risk of Early Recurrence and the Degree of Immune Cell Infiltration in Triple-negative Breast Cancer.
Sato K; Miura K; Tamori S; Akimoto K
Cancer Genomics Proteomics; 2024; 21(3):316-326. PubMed ID: 38670590
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
